31,989
Participants
Start Date
September 30, 2011
Primary Completion Date
May 31, 2013
Study Completion Date
November 30, 2013
High Dose Trivalent Inactivated Influenza Vaccine
0.5 mL Intramuscular
Trivalent Inactivated Influenza Vaccine
0.5 mL, Intramuscular
Endwell
Binghamton
Rochester
Rochester
Pittsburgh
Erie
Scranton
Rockville
Columbia
Elkridge
Winchester
Williamsburg
Norfolk
Winston-Salem
Cary
Raleigh
Raleigh
Salisbury
Charlotte
Wilmington
Hickory
Spartanburg
Clinton
Mt. Pleasant
Anderson
Greer
Stockbridge
Jacksonville
DeLand
Melbourne
Pembroke Pine
Coral Gables
Clearwater
Clearwater
Pinellas Park
Sarasota
Crystal River
Brooksville
Mobile
Nashville
Nashville
Bristol
Bardstown
Lexington
Columbus
Cleveland
Akron
Cincinnati
Cincinnati
Mishawaka
Edina
Fargo
Missoula
Chicago
Peoria
St Louis
Kansas City
Prairie Village
Overland Park
Lenexa
Newton
Wichita
Wichita
Bellevue
Omaha
Harrisburg
Norman
Fort Worth
Tomball
San Antonio
Aurora
Colorado Springs
Colorado Springs
Idaho Falls
Boise
West Jordan
South Jordan
Salt Lake City
Salt Lake City
Salt Lake City
Phoenix
Phoenix
Phoenix
Mesa
Mesa
Chandler
Scottsdale
Tempe
Glendale
Glendale
Albuquerque
Las Vega
La Mesa
Oceanside
San Diego
Anaheim
Santa Rosa
Redding
Milford
Milford
Brockton
Haverhill
Newington
Edison
Warwick
Coquitlam
Mount Pearl
Truro
Greater Sudbury
Toronto
Sherbrooke
Bayamón
San Juan
Sanofi Pasteur, a Sanofi Company
INDUSTRY